Cargando…

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID‐19 in the United States

COVID‐19 led to a recent high‐profile proposal to reintroduce oral poliovirus vaccine (OPV) in the United States (U.S.), initially in clinical trials, but potentially for widespread and repeated use. We explore logistical challenges related to U.S. OPV administration in 2020, review the literature r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Kimberly M., Kalkowska, Dominika A., Badizadegan, Kamran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983986/ https://www.ncbi.nlm.nih.gov/pubmed/33084153 http://dx.doi.org/10.1111/risa.13614

Ejemplares similares

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
por: Thompson, Kimberly M., et al.
Publicado: (2023)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Health economic analysis of antiviral drugs in the global polio eradication endgame
por: Badizadegan, Kamran, et al.
Publicado: (2023)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative
por: Thompson, Kimberly M., et al.
Publicado: (2022)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Potential Future Use, Costs, and Value of Poliovirus Vaccines
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Polio by the Numbers—A Global Perspective( )
por: Badizadegan, Kamran, et al.
Publicado: (2022)

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

The impact of disruptions caused by the COVID-19 pandemic on global polio eradication()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
por: Kalkowska, D. A., et al.
Publicado: (2019)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

III. Factors Influencing the Acceptance of Oral Poliovirus Vaccine
por: Cohart, Edward M., et al.
Publicado: (1962)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination
por: Tan, Susanna K., et al.
Publicado: (2020)

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010
por: Wallace, Gregory S., et al.
Publicado: (2016)

Value of biopsy in a cohort of children with high-titer celiac serologies: observation of dynamic policy differences between Europe and North America
por: Badizadegan, Kamran, et al.
Publicado: (2020)

I. Foreword-With a Review of the Past Experiences of the Yale Poliomyelitis Study Unit with Oral Poliovirus Vaccines
por: Paul, John R.
Publicado: (1962)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f3t5stsj7petsos1nfb6eq20bg